The significance of body mass index (BMI) on kidney cancer outcomes

Being overweight or obese is a well-known risk factor for kidney cancer. This study, published in the Journal of Urology, looked at how body mass index (BMI) affects the survival of a total of 50,717 kidney cancer patients. Overweight and obese patients were associated with improved survival compared to patients with normal BMI, while underweight […]

read more

Triggers for delayed treatment in patients with small renal masses undergoing active surveillance

Active surveillance is an acceptable management strategy for patients with small renal masses. It avoids the risks of surgery, preserves renal function, and delays treatment until it is necessary. However, while the selection of patients to undergo active surveillance is sometimes difficult, all major guidelines and opinion-leaders consider this as an option for patients with […]

read more

How the coronavirus pandemic may affect cancer clinical trials

In this article published in Cancer Therapy Advisor this week, changes to how clinical trials are being conducted due to the health risks posed by COVID-19 to cancer patients are discussed. Some of these changes include the use of telemedicine visits, electronic signatures for signing patient consent forms, posting oral medicines to patients’ homes, and […]

read more

ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

In a paper presented at this year’s European Society of Medical Oncology (ESMO) 2020 virtual congress, Dr Zeynep Zengin from City of Hope Hospital, Los Angeles, USA presented the results of a study using a commercially available circulating tumour DNA (ctDNA) assay. Assessment of ctDNA is a non-invasive method to assess genetic alterations in tumours. […]

read more

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]

read more
Showing 1 to 6 of 962 results